MARKET

VIVE

VIVE

Viveve Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.400
-0.290
-7.86%
After Hours: 3.430 +0.03 +0.88% 18:14 02/26 EST
OPEN
3.700
PREV CLOSE
3.690
HIGH
3.720
LOW
3.370
VOLUME
994.70K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
3.030
MARKET CAP
26.65M
P/E (TTM)
-0.0564
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 19)
Benzinga · 02/19 12:25
Viveve Medical Expects 4Q Rev of About $1.9M
Viveve Medical Expects 4Q Rev of About $1.9M
Dow Jones · 02/18 22:28
Viveve estimates Y/Y growth in Q4 revenue
Viveve Medical (VIVE) traded down 1% after hours on estimating Q4 revenue at $1.9M vs. $1.5M in year ago quarter; global sales of disposable treatment tips increased 48% Y/Y.As of Dec. 31, 2020, the
Seekingalpha · 02/18 21:56
BRIEF-Viveve Medical Says Co Has Capital Resources To Support Operations Through Year-End 2022
reuters.com · 02/18 21:52
Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020
ACCESSWIRE · 02/18 21:02
Viveve Recognized for Leadership in Appointing Women to Board of Directors
Colorado Women on Boards Coalition names Viveve as top Colorado public companyENGLEWOOD, CO / ACCESSWIRE / February 9, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Colo...
ACCESSWIRE · 02/09 13:28
BRIEF-Viveve Medical Announces Expansion Of IP Portfolio With Issuance Of S. Korean Patent
reuters.com · 02/02 13:41
Viveve Announces South Korean Patent Titled 'Vaginal Remodeling Device and Method'
ENGLEWOOD, CO / ACCESSWIRE / February 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office
Benzinga · 02/02 13:30
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIVE. Analyze the recent business situations of Viveve Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIVE stock price target is 16.38 with a high estimate of 22.00 and a low estimate of 10.75.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 18.58M
% Owned: 237.09%
Shares Outstanding: 7.84M
TypeInstitutionsShares
Increased
1
4
New
6
36.34K
Decreased
2
3.75K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.65%
Healthcare Equipment & Supplies
-0.63%
Key Executives
Chairman/Independent Director
Steven Basta
Chief Executive Officer/Director
Scott Durbin
Chief Financial Officer/Vice President - Finance
Jim Robbins
Vice President
Sean Shapiro
Director
Debora Jorn
Independent Director
Arlene Morris
Independent Director
Sharon Presnell
  • Dividends
  • Splits
  • Insider Activity
No Data
About VIVE
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Webull offers kinds of Viveve Medical Inc stock information, including NASDAQ:VIVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIVE stock methods without spending real money on the virtual paper trading platform.